【憂鬱症】「Rejoyn™」: FDA首個輔助治療「重度憂鬱症(MDD)」的數位治療藥物

 【憂鬱症】「Rejoyn™」: FDA首個輔助治療「重度憂鬱症(MDD)」的數位治療藥物

 文章出處  

Businesswire 

 

 原文標題  

Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms 

 

 Twitter  

https://x.com/aimedadviser/status/1824989341955109104 

 

 文章序號  

6101 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2024 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.